Introduction
Interleukin-22 (IL-22) occupies a uniquely paradoxical position among cytokines: it is produced exclusively by immune cells yet acts exclusively on non-hematopoietic tissues—epithelial cells of the gut, skin, liver, lung, and pancreas. This fundamental compartmentalization makes IL-22 the primary cytokine bridge between immune surveillance and epithelial tissue homeostasis, positioning it as an essential tool for research into mucosal immunity, barrier biology, and organ-protective signaling.
Discovered in 2000 as "IL-10-related T cell–derived inducible factor" (IL-TIF), IL-22 shares structural homology with the IL-10 cytokine family but operates through a distinct receptor complex expressed almost exclusively on non-immune stromal and epithelial cells. This expression pattern creates a one-way communication channel: immune cell-derived IL-22 instructs barrier tissues to mount antimicrobial defenses and execute cytoprotective programs, without directly activating immune cells themselves.
All content is Research Use Only (RUO). IL-22 recombinant protein is a laboratory reagent for in vitro and preclinical research investigations. Nothing herein constitutes guidance for use in humans or animals.
---
Molecular Structure and IL-10 Family Classification
Four-Helix Bundle Architecture
IL-22 (gene: IL22; UniProt Q9GZX6) is a 146-amino-acid secreted glycoprotein belonging to the class II cytokine superfamily, specifically the IL-10 family that includes IL-10, IL-19, IL-20, IL-24, IL-26, IL-28A/B (IFN-λ2/3), and IL-29 (IFN-λ1). Like all members of this family, IL-22 adopts a compact four-helix bundle (4HB) topology—helices A, B, C, and D assembled in an up-up-down-down arrangement stabilized by an intramolecular disulfide bond between Cys42 and Cys154.
Despite sharing the 4HB fold with IL-10, IL-22 shares only ~22% sequence identity with IL-10 and no binding overlap for the shared receptor subunit IL-10R2 (see below). The 4HB fold of IL-22 is compact (~179 residues as the mature secreted form), making it a relatively small cytokine that diffuses readily through tissue matrices.
Post-Translational Modifications
IL-22 carries N-glycosylation at Asn21 and O-glycosylation sites that contribute to its secretion efficiency and solubility but are not required for receptor binding or biological activity. Recombinant IL-22 produced in E. coli (non-glycosylated) retains full bioactivity, simplifying reagent production for research applications.
---
Receptor Complex: IL-22R1 and IL-10R2
The Heterodimeric Receptor Architecture
IL-22 signals through a heterodimeric receptor complex assembled from two distinct subunits:
IL-22R1 (IL-22RA1 / IL-22Rα1): The primary IL-22-binding subunit. IL-22R1 is the defining receptor component—its tissue-restricted expression determines where IL-22 signals can occur. Critically, IL-22R1 is expressed almost exclusively on non-hematopoietic cells: intestinal epithelium, hepatocytes, keratinocytes, lung alveolar epithelium, pancreatic acinar cells, and renal tubular cells. Hematopoietic cells lack IL-22R1, explaining why IL-22 has no direct effect on T cells, B cells, macrophages, or dendritic cells.
IL-10R2 (IL-10RB / IL-10Rβ): The shared accessory subunit, expressed ubiquitously. IL-10R2 is shared across multiple cytokine receptor complexes: IL-10R (with IL-10R1), IL-22R (with IL-22R1), IL-26R (with IL-20R1), IL-28R (with IL-28RA for IFN-λ1/2/3), and IL-29R. This sharing means that IL-10R2-blocking reagents (antibodies or knock-out strategies) affect multiple cytokine systems simultaneously—an important experimental caveat.
IL-22 binding to IL-22R1 initiates the sequential recruitment of IL-10R2, completing the heterodimeric signaling complex. Binding affinity of IL-22 to IL-22R1 alone is moderate (Kd ~10 nM), with IL-10R2 recruitment stabilizing the full complex.
Restricted Tissue Expression of IL-22R1
The near-total restriction of IL-22R1 to barrier tissues creates a remarkable tissue-specificity principle:
| Tissue/Organ | IL-22R1 Expression Level | Primary IL-22 Effect |
|---|---|---|
| Intestinal epithelium (small intestine, colon) | Very high | Barrier integrity, antimicrobials, mucins |
| Liver (hepatocytes) | High | Hepatoprotection, regeneration, anti-apoptosis |
| Skin (keratinocytes) | High | Antimicrobials, proliferation, wound healing |
| Lung (alveolar epithelium) | Moderate | Barrier defense, antimicrobials |
| Pancreas (acinar cells) | Moderate | Protection against pancreatitis |
| Kidney (tubular epithelium) | Moderate | Tubular protection |
| Immune cells (T cells, B cells, macrophages) | Absent/minimal | No direct effect |
---
Signal Transduction: JAK/STAT3 and Parallel Pathways
Primary JAK1-TYK2/STAT3 Cascade
IL-22 receptor signaling is canonically mediated through receptor-associated Janus kinases:
- •JAK1 associates constitutively with the intracellular domain of IL-22R1
- •TYK2 associates with the intracellular domain of IL-10R2
Upon IL-22/IL-22R1/IL-10R2 complex formation:
1. JAK1 and TYK2 transphosphorylate each other (activation)
2. Phosphorylated receptor cytoplasmic tails create docking sites for STAT3
3. STAT3 is recruited, phosphorylated at Tyr705 by JAK1/TYK2
4. Phospho-STAT3 homodimerizes and translocates to the nucleus
5. STAT3 binds GAS elements (TTCNNNGAA) in target gene promoters
6. Transcriptional activation of proliferation, survival, and antimicrobial gene programs
STAT3 is the primary transcriptional mediator of IL-22 biology across all target tissues. STAT3 Tyr705 phosphorylation is the canonical readout for IL-22 receptor engagement in research assays.
Parallel Signaling Pathways
Beyond STAT3, IL-22R engagement activates:
MAPK pathways:
- •ERK1/2 (via Ras-Raf-MEK cascade): promotes epithelial cell proliferation
- •p38-MK2: contributes to acute-phase gene induction and inflammatory context integration
- •JNK: context-dependent; may contribute to apoptotic resistance
PI3K-AKT pathway:
- •Activated downstream of JAK kinases via IRS-1 scaffolding
- •AKT promotes cell survival through mTOR activation and FOXO3 nuclear exclusion
- •Contributes to the anti-apoptotic program in hepatocytes and intestinal epithelial cells
The combination of STAT3 and AKT activation explains the potent cytoprotective phenotype of IL-22 signaling—transcription of survival genes is reinforced by post-translational phosphorylation of anti-apoptotic proteins.
---
IL-22 Binding Protein (IL-22BP / IL-22RA2): The Decoy Receptor
Structure and Extraordinary Affinity
IL-22BP (encoded by IL22RA2) is a naturally secreted soluble receptor that lacks a transmembrane domain and cytoplasmic signaling region. It is structurally related to the extracellular domain of IL-22R1 and binds IL-22 with remarkably high affinity—estimated Kd values 10–1,000-fold tighter than the membrane-bound IL-22R1 complex (Xu et al., PMC, 2021).
Three splice isoforms of IL-22BP exist (IL-22BPi1, IL-22BPi2, IL-22BPi3), with IL-22BPi2 being the primary secreted form that efficiently neutralizes IL-22 in the extracellular space. IL-22BPi1 is predominantly intracellular and may function as a regulator of endoplasmic reticulum stress responses.
Expression and Regulation
IL-22BP is expressed primarily by:
- •Plasmacytoid dendritic cells (pDCs) — major systemic source
- •Intestinal myeloid cells — key local regulator of gut IL-22 tone
- •Lung macrophages
A landmark 2024 study demonstrated that IL-22BP knockout mice (Il22ra2−/−) show superior protection against Clostridioides difficile and Citrobacter rodentium infections, attributable to unrestricted IL-22 activity that pre-arms the epithelial antimicrobial response before pathogen arrival (PNAS, 2024). This finding directly demonstrates IL-22BP's in vivo restraining function on IL-22-mediated barrier immunity.
IL-22BP expression is regulated by TNF and NF-κB—with TNF inducing IL-22BP in intestinal myeloid cells, providing a negative feedback mechanism that limits IL-22 activity during acute inflammatory flares. Conversely, IL-22BP is downregulated in the damaged intestinal epithelium, releasing IL-22 activity precisely when mucosal repair is needed.
In research settings, IL-22BP serves as:
1. A functional IL-22 neutralization control to confirm specificity
2. A mechanistic probe for dissecting IL-22BP-regulated vs. IL-22BP-independent biology
3. A readout of local IL-22 regulatory tone in primary tissue samples
---
Cellular Sources of IL-22
Adaptive Immune Producers
Th17 cells: The canonical adaptive source of IL-22. Th17 differentiation (driven by IL-6 + TGF-β → RORγt) co-expresses IL-17A and IL-22, though the two cytokines can be uncoupled—"Th22 cells" primarily producing IL-22 without IL-17A have been characterized in human skin and gut. IL-23 is required for maintenance of Th17/Th22 IL-22 production in established inflammation.
Th22 cells: A distinct CD4+ T cell population defined by high IL-22 but minimal IL-17A or IFN-γ production, expressing CCR4, CCR6, and CCR10. Th22 cells predominate in human epidermis and participate in skin barrier defense programs. Differentiation requires IL-6 + TNF (or IL-21/IL-23) acting on naive CD4+ T cells through AhR-dependent pathways.
γδ T cells: Express RORγt and produce substantial IL-22 in the intestinal intraepithelial compartment, contributing to homeostatic barrier maintenance independent of classical Th17 differentiation.
NK cells and NKT cells: IL-22-producing NK cells (NKp44+ in humans) represent an innate adaptive bridge; their IL-22 production is driven by IL-23 + NF-κB-activating signals from microbial exposure.
Innate Immune Producers: ILC3s
Group 3 Innate Lymphoid Cells (ILC3s) are the dominant innate source of IL-22, particularly in the intestine and lung. ILC3s lack antigen-specific receptors but express NKp44, CCR6, and RORγt, and respond rapidly to cytokine signals (IL-23, IL-1β) from activated dendritic cells and macrophages.
The Aryl Hydrocarbon Receptor (AhR) is a critical transcription factor for intestinal ILC3 IL-22 production. AhR ligands—including dietary indoles (indole-3-carbinol from cruciferous vegetables), tryptophan metabolites (indole, indole-3-acetic acid), and microbially-derived molecules—activate AhR in ILC3s, driving IL-22 transcription and subsequent REG3γ production in the epithelium. This AhR/ILC3/IL-22 axis represents a key mechanism by which diet and microbiome composition regulate intestinal antimicrobial defense (AhR/IL-22 axis review, Frontiers in Immunology, 2025).
---
Intestinal Biology: The Paradigmatic IL-22 Target Tissue
Barrier Integrity and Tight Junction Regulation
IL-22 strengthens the intestinal epithelial barrier through STAT3-dependent transcriptional upregulation of:
- •Tight junction proteins: Claudin-1, occludin, ZO-1, JAM-A — reducing paracellular permeability
- •Adherens junction components: E-cadherin — stabilizing epithelial cell-cell contacts
- •Mucins: MUC1, MUC3, MUC10 — augmenting the protective mucus layer overlying the epithelium
The net effect is a thicker, less permeable epithelial barrier that resists bacterial translocation. In in vitro transwell permeability assays (TEER measurement), IL-22 treatment dose-dependently increases TEER values and reduces FITC-dextran flux across confluent epithelial monolayers—establishing it as a key positive control for barrier-enhancing interventions.
Antimicrobial Peptide Induction: The REG3 Program
IL-22's most studied epithelial function is the induction of antimicrobial peptides (AMPs) that sculpt the gut microbiome and defend against pathogens:
REG3α (human) / REG3γ (mouse): C-type lectins that form membrane-disrupting oligomers targeting gram-positive bacteria. REG3γ creates a spatial separation between microbiota and the epithelium in the small intestinal lumen, preventing microbial colonization of the sterile epithelial surface.
REG3β: Expressed in pancreatic and intestinal contexts; anti-gram-positive activity complementary to REG3γ.
β-Defensins (hBD1, hBD2, hBD3): Short cationic peptides that disrupt gram-negative and gram-positive microbial membranes. IL-22 drives hBD2 and hBD3 expression via STAT3 in colonocytes and keratinocytes.
S100A8/A9 (Calprotectin): Calcium-binding antimicrobial proteins induced by IL-22 in intestinal epithelium; have metal-sequestering (zinc, manganese, iron) antimicrobial activity.
The AMP induction program explains why IL-22 is disproportionately important during early infection responses: recombinant IL-22 administered before pathogen challenge (in preclinical models) pre-arms the epithelium and confers significant protection—before adaptive immunity has time to engage.
Proliferation and Regeneration
STAT3 activation downstream of IL-22 drives intestinal epithelial cell proliferation through upregulation of:
- •Cyclin D1 and Cyclin D2 — G1/S cell cycle progression
- •PCNA — DNA synthesis marker
- •Survivin (BIRC5) — anti-apoptotic IAP family member
This proliferative program enables rapid crypt regeneration after epithelial damage. In colitis mouse models, IL-22 administration accelerates crypt repair and reduces ulceration severity, establishing its utility as a barrier regeneration research reagent.
---
Liver Biology: Hepatoprotective Signaling
The liver is the second major paradigmatic IL-22 target tissue, and hepatocytes express among the highest IL-22R1 levels of any cell type. IL-22/STAT3 signaling in hepatocytes drives a comprehensive cytoprotective program:
Anti-Apoptotic Mechanisms
- •Bcl-2 and Bcl-xL upregulation: Inhibit cytochrome c release from mitochondria
- •Mcl-1 stabilization: Rapid anti-apoptotic response in acute injury
- •Survivin induction: Inhibitor of Apoptosis Protein (IAP) family member
- •FOXO3 nuclear exclusion: AKT-mediated phosphorylation prevents FOXO3-driven pro-apoptotic gene expression
Anti-Oxidative Program
IL-22 activates NRF2-dependent and STAT3-dependent anti-oxidative responses:
- •Mn-SOD (SOD2): Mitochondrial superoxide dismutase
- •Catalase: H2O2 detoxification
- •Glutathione peroxidase and glutathione-S-transferases: Electrophile detoxification
This anti-oxidative program is particularly relevant to ischemia-reperfusion injury research, where reactive oxygen species (ROS) are primary mediators of hepatocellular damage. IL-22 preconditioning in liver transplant and hepatectomy models significantly reduces ROS-mediated injury (PMC, 2022).
Liver Regeneration Research Applications
IL-22 promotes hepatocyte proliferation through cyclin D1 and PCNA induction, synergizing with HGF (hepatocyte growth factor) and EGF in liver regeneration models. In acute-on-chronic liver failure (ACLF) mouse models, recombinant IL-22 or IL-22 Fc fusion proteins partially restore impaired hepatocyte proliferation and reduce injury markers, establishing IL-22 as a research probe for regenerative hepatology.
In alcoholic hepatitis research, IL-22 reverses alcohol-suppressed REG3γ and defensin levels in the intestine, reducing bacterial translocation that drives systemic inflammation and secondary hepatocellular damage (PMC, 2023).
---
Skin Biology: Epidermal Barrier and Antimicrobial Defense
In the skin, IL-22 is produced predominantly by Th22 and Th17 cells attracted by CCL20 (produced by activated keratinocytes), creating an autocrine-like loop:
IL-22 effects in keratinocytes:
- •Promotes terminal differentiation and wound healing via STAT3
- •Induces S100A7 (psoriasin), S100A8, S100A9 — antimicrobial barrier proteins
- •Upregulates hBD2, hBD3 — membrane-disrupting defensins targeting Staphylococcus aureus
- •Drives keratinocyte hyperproliferation (PCNA, Ki-67 elevation)
In psoriasis research models, high IL-22 drives the epidermal acanthosis (thickening) and parakeratosis (retention of nuclei) characteristic of psoriatic plaques. Elevated IL-22 correlates with disease severity, and blocking IL-22 reduces epidermal hyperproliferation in ex vivo skin culture models. However, IL-22 simultaneously induces antimicrobial peptides that reduce S. aureus colonization—illustrating its dual role as a tissue-remodeling cytokine with protective antimicrobial functions.
---
AhR-IL-22 Axis: Diet, Microbiome, and Epithelial Immunity
The Aryl Hydrocarbon Receptor (AhR) represents a critical convergence point between environmental signals, microbial metabolites, and IL-22 production. AhR is a ligand-activated transcription factor expressed in ILC3s and Th22 cells that, upon binding to AhR ligands, translocates to the nucleus and drives IL-22 gene transcription.
AhR ligands relevant to gut IL-22 research:
| Ligand Source | Example Ligand | Pathway |
|---|---|---|
| Dietary tryptophan (microbial conversion) | Indole, Indole-3-acetic acid | Microbiome-AhR-ILC3-IL-22 axis |
| Cruciferous vegetables | Indole-3-carbinol (I3C), DIM | Dietary AhR-ILC3-IL-22 axis |
| High-fat diet depletion | Reduced tryptophan metabolites | Dysbiosis → ↓IL-22 → ↓REG3γ |
| Bacterial products | Various small molecules | Innate sensing-AhR-ILC3 |
This axis explains why dietary fiber (fermented to short-chain fatty acids and indoles) supports mucosal immunity, and why dysbiotic states associated with obesity or antibiotic overuse reduce intestinal IL-22 tone and barrier integrity. In preclinical research, AhR agonists (such as FICZ or I3C) are used to model dietary augmentation of the ILC3-IL-22-REG3γ axis (AhR/IL-22 axis, Frontiers in Immunology, 2025).
---
IL-22 in Disease Research Models
Inflammatory Bowel Disease Research
IL-22's role in IBD research is complex and context-dependent, exemplifying the double-edged nature of inflammatory cytokines:
Protective role (acute inflammation):
- •IL-22 maintains barrier integrity and accelerates epithelial repair
- •REG3γ induction controls opportunistic bacterial overgrowth during mucosal damage
- •Recombinant IL-22 reduces weight loss and histological injury in DSS colitis models (acute setting)
Potentially pathogenic role (chronic inflammation):
- •Sustained IL-22 drives epithelial hyperproliferation that may contribute to dysplasia
- •IL-22 can synergize with VEGF-A to promote neo-angiogenesis in chronically inflamed mucosa
- •In established Crohn's disease-like models, IL-22 + IL-17A combination worsens inflammation compared to either alone
This contextual duality makes IL-22 an important control cytokine in IBD research model validation—researchers should include both pro- and anti-IL-22 conditions to disentangle barrier-protective from proliferative effects.
Pancreatic Research Models
Pancreatic acinar cells express IL-22R1, and IL-22 signaling reduces cerulein-induced acute pancreatitis severity in mouse models through anti-apoptotic and anti-oxidative STAT3 programs. Conversely, chronic pancreatic IL-22 signaling may promote desmoplastic reactions relevant to pancreatic cancer biology—an active area of investigation.
Cancer Research Context
IL-22 drives STAT3 activation in tumor cells expressing IL-22R1 (colorectal cancer, hepatocellular carcinoma, gastric cancer), potentially contributing to cancer cell survival, proliferation, and resistance to apoptosis. Research models use recombinant IL-22 to test its effects on tumor cell line proliferation (HCT116, HT29, HepG2) via proliferation assays, STAT3 phospho-flow cytometry, and gene expression analysis of STAT3 target genes. The dual role—protective in normal epithelium but potentially tumor-promoting in established malignancy via the same STAT3 pathway—makes IL-22 a valuable mechanistic probe for studying STAT3 oncobiology (IL-22 in liver cancer, IJBS, 2020).
---
Research Reagent Applications
Standard Assay Protocols
| Assay | IL-22 Concentration | Target Cell | Readout |
|---|---|---|---|
| REG3γ/hBD2 AMP induction | 10–100 ng/mL | Intestinal epithelial cells (Caco-2, HT-29, colonoids) | ELISA, qPCR |
| STAT3 phosphorylation | 1–50 ng/mL | Any IL-22R1+ cell line | pSTAT3(Y705) Western blot or flow |
| Transepithelial electrical resistance (TEER) | 10–50 ng/mL | Tight junction assay (transwell) | Ohm·cm² measurement |
| Hepatocyte protection from apoptosis | 10–100 ng/mL | HepG2, primary hepatocytes | Caspase-3/7 activity, annexin V |
| Keratinocyte antimicrobial response | 10–100 ng/mL | HaCaT, NHEK cells | hBD2, S100A7 ELISA/qPCR |
| ILC3 co-stimulation | 10–50 ng/mL (+ IL-23) | ILC3 sorted or ILC3-like cell lines | IL-22 production loop, NKp44 |
Distinguishing IL-22 from IL-10 in Research Systems
Both IL-22 and IL-10 belong to the IL-10 cytokine family and share IL-10R2 in their receptor complexes, creating potential confounds:
| Feature | IL-22 | IL-10 |
|---|---|---|
| Receptor specificity | IL-22R1 + IL-10R2 | IL-10R1 + IL-10R2 |
| Target cell restriction | Epithelial/stromal cells ONLY | Immune cells (macrophages, DCs, T cells) primarily |
| Primary signaling | STAT3 (dominant) | STAT3 (dominant) |
| Hallmark function | Epithelial barrier, antimicrobials | Immune suppression, anti-inflammatory |
| Relevant neutralization | Anti-IL-22R1 or anti-IL-22 antibody, or IL-22BP | Anti-IL-10R1 or anti-IL-10 antibody |
The shared STAT3 signal means that gene expression readouts alone cannot distinguish IL-22 from IL-10 effects in mixed-cell systems. Cell-type-specific validation using FACS-sorted populations or cell lines lacking one receptor component is essential for mechanistic attribution.
Quality Parameters for Research-Grade IL-22
- •Bioactivity assay: REG3γ or hBD2 induction in HT-29 or Caco-2 cells (ELISA endpoint)
- •STAT3 phosphorylation: pSTAT3(Y705) induction in HepG2 cells by Western blot (ED50 typically 0.5–5 ng/mL)
- •Endotoxin: <1 EU/μg (critical for separating LPS from IL-22 effects on epithelial cells)
- •IL-22BP binding: SPR or ELISA-based binding assay confirms IL-22 accessibility (unoccupied by IL-22BP)
---
Summary and Research Landscape
IL-22's unique biology—produced by immune cells, acting on non-immune barrier tissues—makes it an indispensable reagent for research spanning mucosal immunology, gut microbiome studies, hepatology, skin biology, and cancer research. The STAT3-centric signaling program it activates in epithelial cells drives a multi-pronged protective response: tighter junctions, abundant antimicrobial peptides, proliferative regeneration, and resistance to apoptosis.
The AhR/ILC3/IL-22 axis linking diet and microbiome composition to mucosal antimicrobial defense continues to generate significant research interest in 2024–2025, particularly in the context of metabolic disease, dysbiosis, and the gut-liver axis. Simultaneously, the discovery that IL-22BP knockout enhances protection against enteric infection (PNAS 2024) has renewed interest in IL-22BP as a regulatable brake on epithelial immunity—with implications for understanding how IBD therapies might modulate local IL-22 bioavailability.
For research laboratories studying intestinal organoids, liver injury models, skin biology, mucosal immunology, or STAT3 oncobiology, recombinant IL-22 (and IL-22BP for neutralization controls) are essential and mechanistically rich research tools.
Related research profiles on this platform: IL-10 | IL-17A | IL-23 | CXCL12/SDF-1
---
Research Use Only. IL-22 recombinant protein is a laboratory reagent for in vitro and preclinical research investigations. Not for diagnostic, therapeutic, or use in humans or animals. All experimental work should comply with applicable biosafety regulations and institutional guidelines.